Onco360 joins limited-distribution network for Tarceva

NEW YORK — A cancer drug made by Genentech and Astellas is no longer available through ordinary retail channels and is now available only through a limited-distribution network.

Cancer-focused specialty pharmacy Onco360 said that effective Monday, the drug Tarceva (erlotinib) would no longer be available through retail pharmacies and that had joined a limited-distribution network that the drug makers had set up for the drug. Tarceva is used for treating advanced non-small cell lung cancer and pancreatic cancer.

"The Onco360 model of oncology-focused pharmacy care continues to resonate with oncologists and patients, and we are very pleased that manufacturers continue to acknowledge that by including Onco360 in their limited-distribution networks," Onco360 SVP trade channel strategy relations Ron Bookman said.